Department of Radiology, Seoul St. Mary's Hospital College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Diagn Interv Radiol. 2023 Nov 7;29(6):832-837. doi: 10.4274/dir.2023.232311. Epub 2023 Sep 11.
To compare tumor perfusion on cone-beam computed tomography (CBCT) after hepatic artery infusion port implantation with the tumor response to hepatic arterial infusion chemotherapy (HAIC) in patients with hepatocellular carcinoma (HCC).
This retrospective study was conducted in patients with advanced HCC treated with HAIC from 2015 to 2020. We performed CBCT with contrast injection via a port on the day following implantation. We classified tumor perfusion on CBCT into three groups: hyperperfusion, isoperfusion, and hypoperfusion. We also evaluated tumor response to HAIC on follow-up images using RECIST 1.1 and compared it with tumor perfusion on CBCT.
This study included 206 tumors in 193 patients (mean: 60.5 years) with HCC. There were 100 hyperperfusion tumors (48.5%), 92 isoperfusion tumors (44.7%), and 14 hypoperfusion tumors (6.8%). The tumor response to HAIC included 10 tumors with a complete response (CR) (4.9%), 66 tumors with a partial response (32%), 60 tumors with stable disease (29.1%), and 70 tumors with progressive disease (34%). Hyperperfusion tumors had a 65% objective response rate (ORR) and a 92% disease control rate (DCR). Isoperfusion tumors had a 12% ORR and a 46.8% DCR, while hypoperfusion tumors had a 0% ORR and a 7.1% DCR. A CR was shown only in hyperperfusion tumors. The ORR and DCR of the three groups were different, with statistical significance ( < 0.001).
Hyperperfusion tumors on CBCT showed a better tumor response to HAIC, with a 65% ORR in patients with HCC. Tumor perfusion on CBCT after implantation of the hepatic arterial infusion port was associated with the tumor response to HAIC.
比较肝癌患者肝动脉灌注化疗(HAIC)置管后锥形束 CT(CBCT)上肿瘤灌注与肿瘤对 HAIC 的反应。
本回顾性研究纳入了 2015 年至 2020 年期间接受 HAIC 治疗的晚期 HCC 患者。我们在置管后第二天进行了带有对比剂注射的 CBCT。我们将 CBCT 上的肿瘤灌注分为三组:高灌注、等灌注和低灌注。我们还使用 RECIST 1.1 评估了随访图像上的肿瘤对 HAIC 的反应,并将其与 CBCT 上的肿瘤灌注进行了比较。
本研究共纳入了 193 名患者的 206 个 HCC 肿瘤(平均年龄:60.5 岁)。其中 100 个肿瘤为高灌注(48.5%),92 个肿瘤为等灌注(44.7%),14 个肿瘤为低灌注(6.8%)。HAIC 的肿瘤反应包括 10 个完全缓解(CR)(4.9%)、66 个部分缓解(32%)、60 个疾病稳定(29.1%)和 70 个疾病进展(34%)。高灌注肿瘤的客观缓解率(ORR)为 65%,疾病控制率(DCR)为 92%。等灌注肿瘤的 ORR 为 12%,DCR 为 46.8%,而低灌注肿瘤的 ORR 为 0%,DCR 为 7.1%。仅在高灌注肿瘤中出现了 CR。三组的 ORR 和 DCR 不同,差异有统计学意义(<0.001)。
CBCT 上的高灌注肿瘤对 HAIC 有更好的肿瘤反应,HCC 患者的 ORR 为 65%。肝动脉灌注化疗置管后 CBCT 上的肿瘤灌注与肿瘤对 HAIC 的反应相关。